Pharmacodynamic and pharmacokinetic assessment of pulmonary rehabilitation mixture for the treatment of pulmonary fibrosis

Abstract Pulmonary rehabilitation mixture (PRM), a Chinese herbal medicine formula, has been used to treat pulmonary fibrosis for decades. In this study, we systematically evaluated the pharmacodynamic and pharmacokinetic performance of PRM. The pharmacodynamic results showed that PRM could improve...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Juanjuan Zhao, Yan Ren, Yubei Qu, Wanglin Jiang, Changjun Lv
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/121ab20e0e60459e8a32835b7b03323a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:121ab20e0e60459e8a32835b7b03323a
record_format	dspace
spelling	oai:doaj.org-article:121ab20e0e60459e8a32835b7b03323a2021-12-02T11:52:22ZPharmacodynamic and pharmacokinetic assessment of pulmonary rehabilitation mixture for the treatment of pulmonary fibrosis10.1038/s41598-017-02774-12045-2322https://doaj.org/article/121ab20e0e60459e8a32835b7b03323a2017-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-02774-1https://doaj.org/toc/2045-2322Abstract Pulmonary rehabilitation mixture (PRM), a Chinese herbal medicine formula, has been used to treat pulmonary fibrosis for decades. In this study, we systematically evaluated the pharmacodynamic and pharmacokinetic performance of PRM. The pharmacodynamic results showed that PRM could improve the condition of CoCl2-stimulated human type II alveolar epithelial cells, human pulmonary microvascular endothelial cells, human lung fibroblasts and pulmonary fibrosis rats induced by bleomycin, PRM treatment reduced the expression of platelet-derived growth factor, fibroblast growth factor, toll-like receptor 4, high-mobility group box protein 1 and hypoxia-inducible factor 1α. In the pharmacokinetic study, an accurate and sensitive ultra-high performance liquid chromatography tandem mass spectrometry method was developed and validated for the simultaneous determination of calycosin, calycosin-7-O-glucoside, formononetin, ononin and mangiferin of PRM in the rat plasma for the first time. The method was then successfully applied to the comparative pharmacokinetic study of PRM in normal and pulmonary fibrosis rats. The five constituents could be absorbed in the blood after the oral administration of PRM and exhibited different pharmacokinetic behaviors in normal and pulmonary fibrosis rats. In summary, PRM exhibited a satisfactory pharmacodynamic and pharmacokinetic performance, which highlights PRM as a potential multi-target oral drug for the treatment of pulmonary fibrosis.Juanjuan ZhaoYan RenYubei QuWanglin JiangChangjun LvNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-13 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Juanjuan Zhao Yan Ren Yubei Qu Wanglin Jiang Changjun Lv Pharmacodynamic and pharmacokinetic assessment of pulmonary rehabilitation mixture for the treatment of pulmonary fibrosis
description	Abstract Pulmonary rehabilitation mixture (PRM), a Chinese herbal medicine formula, has been used to treat pulmonary fibrosis for decades. In this study, we systematically evaluated the pharmacodynamic and pharmacokinetic performance of PRM. The pharmacodynamic results showed that PRM could improve the condition of CoCl2-stimulated human type II alveolar epithelial cells, human pulmonary microvascular endothelial cells, human lung fibroblasts and pulmonary fibrosis rats induced by bleomycin, PRM treatment reduced the expression of platelet-derived growth factor, fibroblast growth factor, toll-like receptor 4, high-mobility group box protein 1 and hypoxia-inducible factor 1α. In the pharmacokinetic study, an accurate and sensitive ultra-high performance liquid chromatography tandem mass spectrometry method was developed and validated for the simultaneous determination of calycosin, calycosin-7-O-glucoside, formononetin, ononin and mangiferin of PRM in the rat plasma for the first time. The method was then successfully applied to the comparative pharmacokinetic study of PRM in normal and pulmonary fibrosis rats. The five constituents could be absorbed in the blood after the oral administration of PRM and exhibited different pharmacokinetic behaviors in normal and pulmonary fibrosis rats. In summary, PRM exhibited a satisfactory pharmacodynamic and pharmacokinetic performance, which highlights PRM as a potential multi-target oral drug for the treatment of pulmonary fibrosis.
format	article
author	Juanjuan Zhao Yan Ren Yubei Qu Wanglin Jiang Changjun Lv
author_facet	Juanjuan Zhao Yan Ren Yubei Qu Wanglin Jiang Changjun Lv
author_sort	Juanjuan Zhao
title	Pharmacodynamic and pharmacokinetic assessment of pulmonary rehabilitation mixture for the treatment of pulmonary fibrosis
title_short	Pharmacodynamic and pharmacokinetic assessment of pulmonary rehabilitation mixture for the treatment of pulmonary fibrosis
title_full	Pharmacodynamic and pharmacokinetic assessment of pulmonary rehabilitation mixture for the treatment of pulmonary fibrosis
title_fullStr	Pharmacodynamic and pharmacokinetic assessment of pulmonary rehabilitation mixture for the treatment of pulmonary fibrosis
title_full_unstemmed	Pharmacodynamic and pharmacokinetic assessment of pulmonary rehabilitation mixture for the treatment of pulmonary fibrosis
title_sort	pharmacodynamic and pharmacokinetic assessment of pulmonary rehabilitation mixture for the treatment of pulmonary fibrosis
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/121ab20e0e60459e8a32835b7b03323a
work_keys_str_mv	AT juanjuanzhao pharmacodynamicandpharmacokineticassessmentofpulmonaryrehabilitationmixtureforthetreatmentofpulmonaryfibrosis AT yanren pharmacodynamicandpharmacokineticassessmentofpulmonaryrehabilitationmixtureforthetreatmentofpulmonaryfibrosis AT yubeiqu pharmacodynamicandpharmacokineticassessmentofpulmonaryrehabilitationmixtureforthetreatmentofpulmonaryfibrosis AT wanglinjiang pharmacodynamicandpharmacokineticassessmentofpulmonaryrehabilitationmixtureforthetreatmentofpulmonaryfibrosis AT changjunlv pharmacodynamicandpharmacokineticassessmentofpulmonaryrehabilitationmixtureforthetreatmentofpulmonaryfibrosis
_version_	1718395031489871872

Pharmacodynamic and pharmacokinetic assessment of pulmonary rehabilitation mixture for the treatment of pulmonary fibrosis

Ejemplares similares